Skip to main content
Fig. 8 | Journal of Hematology & Oncology

Fig. 8

From: Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases

Fig. 8

AD0157 blocks VEGFR-3 and VEGFR-2 signaling cascades in LECs. a Values of VEGFR-3 and VEGFR-2 mRNA expression levels in LECs incubated with different AD0157 concentrations. b Representative Western-blots showing the effect of AD0157 on VEGFR-3, VEGFR-2, ERK1/2, and Akt phosphorylations after stimulation with rhVEGF-C (400 ng/mL), rhVEGF-C156S (500 ng/mL), or rhVEGF-A (100 ng/m). c Quantification by densitometry of Western blots. Results are expressed as the percentage of phosphorylated proteins/total protein ± s.e.m. of five Western blots. The Mann-Whitney-Wilcoxon test was used to determine if the differences among control (stimulated LECs without AD0157 treatment) and AD0157-treated and stimulated LECs were statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001 versus control

Back to article page